Highlights
- Market Cap
- $1.46B
- Enterprise Value
- $1.61B
- EPS (TTM)
- -$10.15
- Total Revenue (TTM)
- $55.23M
- Gross Profit (TTM)
- $55.04M
- EBITDA (TTM)
- -$122.97M
- Year Range
- $6.48 - $77.97
- Target Price
- $136.40
- ROA (TTM)
- -58.51%
- ROE (TTM)
- -182.65%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Nektar Therapeutics, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Nektar Therapeutics (NKTR) has returned 70.18% so far this year and 605.39% over the past 12 months. Over the last ten years, NKTR has returned -10.44% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Nektar Therapeutics
- 1D
- 10.27%
- 1M
- 4.31%
- YTD
- 70.18%
- 6M
- 26.45%
- 1Y
- 605.39%
- 3Y*
- 89.68%
- 5Y*
- -25.14%
- 10Y*
- -10.44%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since May 3, 1994, NKTR's average daily return is +0.11%, while the average monthly return is +2.12%. At this rate, your investment would double in approximately 2.8 years.
Historically, 48% of months were positive and 52% were negative. The best month was Jun 2025 with a return of +137.8%, while the worst month was Feb 2023 at -49.3%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.
On a daily basis, NKTR closed higher 46% of trading days. The best single day was Jun 24, 2025 with a return of +156.3%, while the worst single day was Mar 14, 2022 at -60.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.71% | 84.78% | 4.31% | 70.18% | |||||||||
| 2025 | -11.04% | 1.54% | -19.05% | 16.99% | -8.93% | 137.77% | -16.10% | 37.73% | 90.56% | 14.11% | 0.43% | -35.16% | 203.08% |
| 2024 | -4.02% | 30.92% | 31.58% | 56.28% | -13.01% | -2.36% | 8.06% | -4.48% | 1.56% | -8.46% | -4.20% | -18.42% | 64.60% |
| 2023 | 20.35% | -49.26% | -49.07% | 7.03% | -22.89% | -0.84% | -6.85% | 11.05% | 0.10% | -21.26% | 4.48% | 15.31% | -75.00% |
| 2022 | -17.69% | -7.91% | -47.36% | -23.38% | -15.74% | 9.20% | 4.21% | -0.51% | -18.78% | 17.50% | -25.53% | -19.29% | -83.27% |
| 2021 | 15.88% | 15.18% | -11.86% | -1.95% | -7.85% | -5.04% | -7.98% | -1.96% | 16.02% | -15.59% | -25.73% | 19.98% | -20.53% |
Benchmark Metrics
Nektar Therapeutics has an annualized alpha of 15.25%, beta of 1.32, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since May 04, 1994.
- This stock participated in 138.71% of S&P 500 Index downside but only 107.72% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.25%
- Beta
- 1.32
- R²
- 0.11
- Upside Capture
- 107.72%
- Downside Capture
- 138.71%
Return for Risk
Risk / Return Rank
NKTR ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and compare them to a chosen benchmark (S&P 500 Index).
| NKTR | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.23 | 0.90 | +2.33 |
Sortino ratioReturn per unit of downside risk | 5.66 | 1.39 | +4.28 |
Omega ratioGain probability vs. loss probability | 1.64 | 1.21 | +0.43 |
Calmar ratioReturn relative to maximum drawdown | 11.81 | 1.40 | +10.41 |
Martin ratioReturn relative to average drawdown | 28.66 | 6.61 | +22.05 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore NKTR risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nektar Therapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nektar Therapeutics was 99.61%, occurring on Nov 28, 2023. The portfolio has not yet recovered.
The current Nektar Therapeutics drawdown is 95.58%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.61% | Mar 9, 2018 | 1441 | Nov 28, 2023 | — | — | — |
| -95.53% | Mar 8, 2000 | 2165 | Oct 15, 2008 | 2324 | Jan 9, 2018 | 4489 |
| -41.1% | Oct 15, 1997 | 251 | Oct 13, 1998 | 296 | Dec 15, 1999 | 547 |
| -38.17% | May 24, 1996 | 83 | Sep 20, 1996 | 119 | Mar 12, 1997 | 202 |
| -37.78% | Oct 18, 1994 | 123 | Apr 12, 1995 | 88 | Aug 17, 1995 | 211 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nektar Therapeutics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nektar Therapeutics is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NKTR relative to other companies in the Biotechnology industry. Currently, NKTR has a P/S ratio of 21.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NKTR in comparison with other companies in the Biotechnology industry. Currently, NKTR has a P/B value of 16.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |